1
|
Kotanides H, Sattler RM, Lebron MB, Carpenito C, Shen J, Li J, Surguladze D, Haidar JN, Burns C, Shen L, Inigo I, Pennello AL, Forest A, Chen X, Chin D, Sonyi A, Topper M, Boucher L, Sharma P, Zhang Y, Burtrum D, Novosiadly RD, Ludwig DL, Plowman GD, Kalos M. Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity. Mol Cancer Ther 2021; 19:988-998. [PMID: 32241872 DOI: 10.1158/1535-7163.mct-19-0893] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2019] [Revised: 12/17/2019] [Accepted: 02/10/2020] [Indexed: 11/16/2022]
Abstract
The CD137 receptor plays a key role in mediating immune response by promoting T cell proliferation, survival, and memory. Effective agonism of CD137 has the potential to reinvigorate potent antitumor immunity either alone or in combination with other immune-checkpoint therapies. In this study, we describe the discovery and characterization of a unique CD137 agonist, 7A5, a fully human IgG1 Fc effector-null monoclonal antibody. The biological properties of 7A5 were investigated through in vitro and in vivo studies. 7A5 binds CD137, and the binding epitope overlaps with the CD137L binding site based on structure. 7A5 engages CD137 receptor and activates NF-κB cell signaling independent of cross-linking or Fc effector function. In addition, T cell activation measured by cytokine IFNγ production is induced by 7A5 in peripheral blood mononuclear cell costimulation assay. Human tumor xenograft mouse models reconstituted with human immune cells were used to determine antitumor activity in vivo. Monotherapy with 7A5 inhibits tumor growth, and this activity is enhanced in combination with a PD-L1 antagonist antibody. Furthermore, the intratumoral immune gene expression signature in response to 7A5 is highly suggestive of enhanced T cell infiltration and activation. Taken together, these results demonstrate 7A5 is a differentiated CD137 agonist antibody with biological properties that warrant its further development as a cancer immunotherapy. GRAPHICAL ABSTRACT: http://mct.aacrjournals.org/content/molcanther/19/4/988/F1.large.jpg.
Collapse
Affiliation(s)
- Helen Kotanides
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York.
| | | | - Maria B Lebron
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Carmine Carpenito
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Juqun Shen
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Jingxing Li
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - David Surguladze
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Jaafar N Haidar
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Colleen Burns
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Leyi Shen
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Ivan Inigo
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | | | - Amelie Forest
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Xinlei Chen
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Darin Chin
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Andreas Sonyi
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Michael Topper
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Lauren Boucher
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Prachi Sharma
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Yiwei Zhang
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Douglas Burtrum
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | | | - Dale L Ludwig
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Gregory D Plowman
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| | - Michael Kalos
- Lilly Research Laboratories, Eli Lilly and Company, New York, New York
| |
Collapse
|
2
|
Carpenito C, Li Y, Wang GX, Malabunga MS, Haidar JN, Forest A, Murphy MY, Hall GE, Wang C, Shen L, Sonyi A, Chin D, Pennello AL, Inigo IV, Surguladze D, Yao YM, Burtrum D, Novosiadly RD, Persaud K, Ludwig DL, Kalos MD. Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-2730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Modulating the PD-L1/PD-1 axis in man through function blocking antibodies can release potent anti-tumor immunity, leading to durable objective responses across multiple tumor types. Here we describe the discovery and preclinical characterization of LY3300054, a fully human IgG1λ antibody capable of binding human PD-L1 with high affinity and inhibiting binding to its two cognate receptors, PD-1 and CD80.
LY3300054 is an antagonist monoclonal antibody recognizing human PD-L1 with high affinity (KD 0.08 nM), selected and derived from a scFv phage library. LY3300054 was engineered and expressed as an IgG1-Fc null monoclonal antibody to ablate immune effector function. Multiple in vitro assays, including mixed leukocyte reaction (MLR) and tetanus toxoid recall assay were utilized to demonstrate LY3300054 potent functional activity in enhancing the activation of primary human T cells in culture. The biological activity of LY3300054 on T cells was also shown to be enhanced by co-administration of anti-CTLA4 mAb (ipilimumab) in MLR. Further, we evaluated LY3300054 activity in vivo using xenograft mouse tumor models reconstituted with human immune cells. LY3300054 demonstrated anti-tumor activity in both NCI-H292 xenografts co-implanted with human PBMCs and HCC827 xenograft model upon infusion of human T cells. LY3300054 in vivo activity was also tested in HCC827- and Ov79-bearing immunodeficient NSG/NOG mice reconstituted with human hematopoietic stem cells. In this setting, LY3300054 displayed robust anti-tumor and immunomodulatory effects exemplified by T cell inflamed phenotype in the tumor and peripheral tissues. High-content molecular profiling identified distinct gene expression changes indicative of T cell activation in all models tested. A mutational strategy based on integrating the PD-1/PD-L1 structure data with the orthologous sequence data of PD-L1 has identified a residue on PD-L1, which is part of the PD-L1/PD-1 interface, that is critical for the species specificity of LY3300054.
This study demonstrates that LY3300054 is novel anti-PD-L1 monoclonal antibody, capable of potently enhancing human T cell function both in vitro and in vivo, and provides previously not described insights into the effects of PD-L1 blockade on the intra- and extra-tumoral immune response. LY3300054 is currently under clinical evaluation in monotherapy and combination with other therapeutic modalities in multiple tumor types (NCT02791334; NCT03099109; NCT02791334; NCT02791334)
Citation Format: Carmine Carpenito, Yiwen Li, George X. Wang, Maria S. Malabunga, Jaafar N. Haidar, Amelie Forest, Mary Y. Murphy, Gerald E. Hall, Cindy Wang, Leyi Shen, Andreas Sonyi, Darin Chin, Anthony L. Pennello, Ivan V. Inigo, David Surguladze, Yung-mae Yao, Douglas Burtrum, Ruslan D. Novosiadly, Kris Persaud, Dale L. Ludwig, Michael D. Kalos. Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2730.
Collapse
Affiliation(s)
| | - Yiwen Li
- Eli Lilly and Company, New York, NY
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M. Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. J Immunother Cancer 2018; 6:45. [PMID: 29866166 PMCID: PMC5987621 DOI: 10.1186/s40425-018-0354-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Accepted: 05/14/2018] [Indexed: 11/10/2022] Open
Affiliation(s)
- Yiwen Li
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA. .,Eli Lilly and Company, 450 East 29th Street, New York, NY, 10016, USA.
| | - Carmine Carpenito
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - George Wang
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - David Surguladze
- Lilly Research Laboratories, Department of Preclinical Pharmacology, New York, NY, USA
| | - Amelie Forest
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Maria Malabunga
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Mary Murphy
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Yiwei Zhang
- Lilly Research Laboratories, Department of Biologics Technology, New York, NY, USA
| | - Andreas Sonyi
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Darin Chin
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Douglas Burtrum
- Lilly Research Laboratories, Department of Biologics Technology, New York, NY, USA
| | - Ivan Inigo
- Lilly Research Laboratories, Department of Preclinical Pharmacology, New York, NY, USA
| | - Anthony Pennello
- Lilly Research Laboratories, Department of Preclinical Pharmacology, New York, NY, USA
| | - Leyi Shen
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Laurent Malherbe
- Lilly Research Laboratories, Department of Non-Clinical Safety, Indianapolis, IN, USA
| | - Xinlei Chen
- Lilly Research Laboratories, Department of Quantitative Biology, New York, NY, USA
| | - Gerald Hall
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Jaafar N Haidar
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Dale L Ludwig
- Lilly Research Laboratories, Department of Biologics Technology, New York, NY, USA
| | - Ruslan D Novosiadly
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA
| | - Michael Kalos
- Lilly Research Laboratories, Department of Cancer Immunobiology, New York, NY, USA. .,Eli Lilly and Company, 450 East 29th Street, New York, NY, 10016, USA. .,Janssen Pharmaceutical Companies of Johnson and Johnson, Springhouse, PA, USA.
| |
Collapse
|
4
|
Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M. Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. J Immunother Cancer 2018; 6:31. [PMID: 29712568 PMCID: PMC5925824 DOI: 10.1186/s40425-018-0329-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Accepted: 02/20/2018] [Indexed: 12/25/2022] Open
Abstract
Background Modulation of the PD-1/PD-L1 axis through antagonist antibodies that block either receptor or ligand has been shown to reinvigorate the function of tumor-specific T cells and unleash potent anti-tumor immunity, leading to durable objective responses in a subset of patients across multiple tumor types. Results Here we describe the discovery and preclinical characterization of LY3300054, a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors PD-1 and CD80. The functional activity of LY3300054 on primary human T cells is evaluated using a series of in vitro T cell functional assays and in vivo models using human-immune reconstituted mice. LY3300054 is shown to induce primary T cell activation in vitro, increase T cell activation in combination with anti-CTLA4 antibody, and to potently enhance anti-tumor alloreactivity in several xenograft mouse tumor models with reconstituted human immune cells. High-content molecular analysis of tumor and peripheral tissues from animals treated with LY3300054 reveals distinct adaptive immune activation signatures, and also previously not described modulation of innate immune pathways. Conclusions LY3300054 is currently being evaluated in phase I clinical trials for oncology indications. Electronic supplementary material The online version of this article (10.1186/s40425-018-0329-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yiwen Li
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA .,0000 0000 2220 2544grid.417540.3Eli Lilly and Company 450 East 29th Street 10016 New York NY USA
| | - Carmine Carpenito
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - George Wang
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - David Surguladze
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Preclinical Pharmacology New York NY USA
| | - Amelie Forest
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Maria Malabunga
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Mary Murphy
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Yiwei Zhang
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Biologics Technology New York NY USA
| | - Andreas Sonyi
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Darin Chin
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Douglas Burtrum
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Biologics Technology New York NY USA
| | - Ivan Inigo
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Preclinical Pharmacology New York NY USA
| | - Anthony Pennello
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Preclinical Pharmacology New York NY USA
| | - Leyi Shen
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Laurent Malherbe
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Non-Clinical Safety Indianapolis IN USA
| | - Xinlei Chen
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Quantitative Biology New York NY USA
| | - Gerald Hall
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Jaafar N Haidar
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Dale L Ludwig
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Biologics Technology New York NY USA
| | - Ruslan D Novosiadly
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA
| | - Michael Kalos
- 0000 0000 2220 2544grid.417540.3Lilly Research Laboratories, Department of Cancer Immunobiology New York NY USA .,0000 0000 2220 2544grid.417540.3Eli Lilly and Company 450 East 29th Street 10016 New York NY USA.,grid.430674.2Janssen Pharmaceutical Companies of Johnson and Johnson Springhouse PA USA
| |
Collapse
|
5
|
Shen Y, Zeng L, Novosyadlyy R, Forest A, Zhu A, Korytko A, Zhang H, Eastman SW, Topper M, Hindi S, Covino N, Persaud K, Kang Y, Burtrum D, Surguladze D, Prewett M, Chintharlapalli S, Wroblewski VJ, Shen J, Balderes P, Zhu Z, Snavely M, Ludwig DL. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation. MAbs 2016; 7:931-45. [PMID: 26073904 PMCID: PMC4623440 DOI: 10.1080/19420862.2015.1055442] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Bi-specific antibodies (BsAbs), which can simultaneously block 2 tumor targets, have emerged as promising therapeutic alternatives to combinations of individual monoclonal antibodies. Here, we describe the engineering and development of a novel, human bi-functional antibody-receptor domain fusion molecule with ligand capture (bi-AbCap) through the fusion of the domain 2 of human vascular endothelial growth factor receptor 1 (VEGFR1) to an antibody directed against insulin-like growth factor - type I receptor (IGF-IR). The bi-AbCap possesses excellent stability and developability, and is the result of minimal engineering. Beyond potent neutralizing activities against IGF-IR and VEGF, the bi-AbCap is capable of cross-linking VEGF to IGF-IR, leading to co-internalization and degradation of both targets by tumor cells. In multiple mouse xenograft tumor models, the bi-AbCap improves anti-tumor activity over individual monotherapies. More importantly, it exhibits superior inhibition of tumor growth, compared with the combination of anti-IGF-IR and anti-VEGF therapies, via powerful blockade of both direct tumor cell growth and tumor angiogenesis. The unique "capture-for-degradation" mechanism of the bi-AbCap is informative for the design of next-generation bi-functional anti-cancer therapies directed against independent signaling pathways. The bi-AbCap design represents an alternative approach to the creation of dual-targeting antibody fusion molecules by taking advantage of natural receptor-ligand interactions.
Collapse
Affiliation(s)
- Yang Shen
- a Antibody Technology; Eli Lilly and Company ; New York , NY USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Lebron MB, Brennan L, Damoci CB, Prewett MC, O'Mahony M, Duignan IJ, Credille KM, DeLigio JT, Starodubtseva M, Amatulli M, Zhang Y, Schwartz KD, Burtrum D, Balderes P, Persaud K, Surguladze D, Loizos N, Paz K, Kotanides H. A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Cancer Biol Ther 2014; 15:1208-18. [PMID: 24921944 DOI: 10.4161/cbt.29523] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Stem cell factor receptor (c-Kit) exerts multiple biological effects on target cells upon binding its ligand stem cell factor (SCF). Aberrant activation of c-Kit results in dysregulated signaling and is implicated in the pathogenesis of numerous cancers. The development of more specific and effective c-Kit therapies is warranted given its essential role in tumorigenesis. In this study, we describe the biological properties of CK6, a fully human IgG1 monoclonal antibody against the extracellular region of human c-Kit. CK6 specifically binds c-Kit receptor with high affinity (EC 50 = 0.06 nM) and strongly blocks its interaction with SCF (IC 50 = 0.41 nM) in solid phase assays. Flow cytometry shows CK6 binding to c-Kit on the cell surface of human small cell lung carcinoma (SCLC), melanoma, and leukemia tumor cell lines. Furthermore, exposure to CK6 inhibits SCF stimulation of c-Kit tyrosine kinase activity and downstream signaling pathways such as mitogen-activated protein kinase (MAPK) and protein kinase B (AKT), in addition to reducing tumor cell line growth in vitro. CK6 treatment significantly decreases human xenograft tumor growth in NCI-H526 SCLC (T/C% = 57) and Malme-3M melanoma (T/C% = 58) models in vivo. The combination of CK6 with standard of care chemotherapy agents, cisplatin and etoposide for SCLC or dacarbazine for melanoma, more potently reduces tumor growth (SCLC T/C% = 24, melanoma T/C% = 38) compared with CK6 or chemotherapy alone. In summary, our results demonstrate that CK6 is a c-Kit antagonist antibody with tumor growth neutralizing properties and are highly suggestive of potential therapeutic application in treating human malignancies harboring c-Kit receptor.
Collapse
Affiliation(s)
- Maria B Lebron
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Laura Brennan
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Christopher B Damoci
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Marie C Prewett
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Marguerita O'Mahony
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Inga J Duignan
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | | | - James T DeLigio
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Marina Starodubtseva
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Michael Amatulli
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Yiwei Zhang
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Kaben D Schwartz
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Douglas Burtrum
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Paul Balderes
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Kris Persaud
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - David Surguladze
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Nick Loizos
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Keren Paz
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| | - Helen Kotanides
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company; New York, NY USA
| |
Collapse
|
7
|
Lebron M, Brennan L, Damoci C, Prewett M, Starodubtseva M, Amatulli M, Zhang Y, Burtrum D, Balderes P, Persaud K, Surguladze D, Loizos N, Paz K, Kotanides H. Abstract C159: A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-c159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Stem cell factor receptor also known as c-Kit is a receptor tyrosine kinase that mediates cell growth, survival, and differentiation signals in response to its ligand stem cell factor (SCF). Aberrant c-Kit expression and/or activation through mutations or autocrine/paracrine signaling mechanisms occur in various malignancies and promote tumor development. Specific therapeutic targeting of c-Kit in cancer is warranted given its cancer role. In this study, we characterize the biological properties of CK6, a fully human IgG1 monoclonal antibody against the extracellular region of human c-Kit. CK6 specifically binds human c-Kit receptor with high affinity (EC50= 0.06nM) and strongly blocks its interaction with SCF (IC50= 0.41nM) in solid phase assays. Flow cytometry shows CK6 binding to the cell surface of small cell lung carcinoma (SCLC), melanoma, leukemia, and other human c-Kit expressing tumor cell lines. Furthermore, exposure to CK6 inhibits SCF stimulation of c-Kit tyrosine kinase activity and downstream signaling pathways in these tumor cell lines. Reduced levels of phosphorylated c-Kit, mitogen-activated protein kinase (MAPK) and protein kinase B/Akt were observed. Given these findings, we evaluated the antitumor growth efficacy of CK6 in several human xenograft tumor models in vivo. CK6 monotherapy treatment significantly suppressed tumor growth of NCI-H526 SCLC (T/C%= 50) and Malme-3M Melanoma (T/C%= 58) xenograft models. The combination of CK6 with standard of care (SOC) chemotherapy agents, cisplatin and etoposide for SCLC or dacarbazine for melanoma, led to enhanced tumor growth inhibition (SCLC T/C%= 12; melanoma T/C%= 38) compared to CK6 monotherapy or SOC alone. In summary, our results demonstrate that CK6 is a c-Kit antagonist antibody with tumor growth neutralizing properties and are highly suggestive of potential therapeutic application in treating human cancers harboring c-Kit receptor.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C159.
Citation Format: Maria Lebron, Laura Brennan, Chris Damoci, Marie Prewett, Marina Starodubtseva, Michael Amatulli, Yiwei Zhang, Douglas Burtrum, Paul Balderes, Kris Persaud, David Surguladze, Nick Loizos, Keren Paz, Helen Kotanides. A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C159.
Collapse
Affiliation(s)
- Maria Lebron
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | | | - Chris Damoci
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | - Marie Prewett
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | - Marina Starodubtseva
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | - Michael Amatulli
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | - Yiwei Zhang
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | - Douglas Burtrum
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | - Paul Balderes
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | - Kris Persaud
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | - David Surguladze
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | - Nick Loizos
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| | - Keren Paz
- 3Champions Oncology Inc., Hackensack, NJ
| | - Helen Kotanides
- 1ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY
| |
Collapse
|
8
|
Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 2011; 19:89-99. [PMID: 21178280 DOI: 10.3233/hab-2010-0232] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE To evaluate the antibody-dependent cellular cytotoxicity (ADCC) of cetuximab, an anti-epidermal growth factor receptor (EGFR) IgG1 antibody, in vitro. METHODS Binding to human Fc receptors was measured by ELISA. ADCC against a panel of tumor cell lines was evaluated using peripheral blood mononuclear cells or NK cells as effectors and lactate dehydrogenase release as a marker of cell killing. Cetuximab was compared with two glycan variants of cetuximab and with panitumumab, an anti-EGFR IgG2. RESULTS Cetuximab bound with high affinity to FcγRI (EC50 = 0.13 nM) and FcγRIIIa (EC50 = 6 nM) and effectively induced ADCC across multiple tumor cell lines. Panitumumab and aglycosylated cetuximab did not bind to FcγRI or FcγRIIIa nor have ADCC activity even at high effector-target cell ratios, even though the EGFR-binding affinity of cetuximab and panitumumab were shown to be comparable (KD = 87 pM and 83 pM, respectively). The extent of cetuximab-elicited ADCC was associated with the level of EGFR expression on tumor cells. CONCLUSIONS Cetuximab elicits effective ADCC activity against a wide range of tumor cells in vitro. This activity is dependent on antibody glycosylation and IgG1 isotype as well as tumor-cell EGFR expression. These findings suggest that ADCC may contribute to the antitumor activity of cetuximab.
Collapse
Affiliation(s)
- Dipa Patel
- Department of Immunology, ImClone Systems, New York, NY 10014, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res 2010; 16:1191-205. [PMID: 20145179 DOI: 10.1158/1078-0432.ccr-09-1634] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Transforming growth factor beta (TGFbeta) is a pleiotropic cytokine that affects tumor growth, metastasis, stroma, and immune response. We investigated the therapeutic efficacy of anti-TGFbeta receptor II (TGFbeta RII) antibody in controlling metastasis and tumor growth as well as enhancing antitumor immunity in preclinical tumor models. EXPERIMENTAL DESIGN We generated neutralizing antibodies to TGFbeta RII and assessed the antibody effects on cancer, stroma, and immune cells in vitro. The efficacy and mechanism of action of the antibody as monotherapy and in combination with chemotherapy in suppression of primary tumor growth and metastasis were evaluated in several tumor models. RESULTS Anti-TGFbeta RII antibody blocked TGFbeta RII binding to TGFbeta 1, 2, and 3, and attenuated the TGFbeta-mediated activation of downstream Smad2 kinase, invasion of cancer cells, motility of endothelial and fibroblast cells, and induction of immunosuppressive cells. Treatment with the antibody significantly suppressed primary tumor growth and metastasis and enhanced natural killer and CTL activity in tumor-bearing mice. Immunohistochemistry analysis showed cancer cell apoptosis and massive necrosis, and increased tumor-infiltrating T effector cells and decreased tumor-infiltrating Gr-1+ myeloid cells in the antibody-treated tumors. Fluorescence-activated cell sorting analysis indicated the significant reduction of peripheral Gr-1+/CD11b+ myeloid cells in treated animals. Concomitant treatment with the cytotoxic agent cyclophosphamide resulted in a significantly increased antitumor efficacy against primary tumor growth and metastasis. CONCLUSIONS These preclinical data provide a foundation to support using anti-TGFbeta RII antibody as a therapeutic agent for TGFbeta RII-dependent cancer with metastatic capacity.
Collapse
Affiliation(s)
- Zhaojing Zhong
- Department of Antibody Technology & Immunology, Clinical Research, and Research, ImClone Systems, New York, New York 10014, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Deevi D, Burtrum D, Melchior M, Witte L, Ludwig D, Tonra J. 516 POSTER Efficacy of EGFR and IGF-1R antibody therapy is independent of PTEN status in a selection of tumor models. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72450-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
11
|
Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13:5549s-5555s. [PMID: 17875788 DOI: 10.1158/1078-0432.ccr-07-1109] [Citation(s) in RCA: 141] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Targeted monoclonal antibody therapy is an important strategy in cancer therapeutics. Among the most promising characteristics of therapeutic targets are those that modulate the growth and survival of malignant neoplasms and their sensitivity to anticancer therapies. The insulin-like growth factor-I receptor (IGF-IR) is overexpressed in many types of solid and hematopoietic malignancies, and has been implicated as a principal cause of heightened proliferative and survival signaling. IGF-IR has also been shown to confer resistance to cytotoxic, hormonal, and targeted therapies, suggesting that therapeutics targeting IGF-IR may be effective against a broad range of malignancies. IMC-A12 (ImClone Systems Incorporated), a fully human monoclonal IgG1 antibody that binds with high affinity to the IGF-IR, inhibits ligand-dependent receptor activation and downstream signaling. IMC-A12 also mediates robust internalization and degradation of the IGF-IR. In human tumor xenograft models, IGF-IR blockade by IMC-A12 results in rapid and profound growth inhibition of cancers of the breast, lung, colon, and pancreas, and many other neoplasms. Although promising single-agent activity has been observed, the most impressive effects of targeting the IGF-IR with IMC-A12 have been noted when this agent was combined with cytotoxic agents or other targeted therapeutics. The results with IMC-A12 to date suggest that it may be an effective therapeutic in a diverse array of oncologic indications.
Collapse
Affiliation(s)
- Eric K Rowinsky
- Department of Clinical Research and Regulatory Affairs, ImClone Systems Incorporated, Branchburg, New Jersey 08876, USA.
| | | | | | | | | | | |
Collapse
|
12
|
Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MAS. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007; 56:343-57. [PMID: 16832681 PMCID: PMC11031103 DOI: 10.1007/s00262-006-0196-9] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2006] [Accepted: 05/23/2006] [Indexed: 12/12/2022]
Abstract
Although many multiple myeloma (MM) patients initially respond to cytotoxic therapy, most eventually relapse. Novel therapeutic strategies employing a combination of chemotherapy with targeted biologics may significantly enhance the response of tumor cells to treatment. We tested a fully human anti-IGF-IR antibody (A12) against MM, and showed specific inhibition of IGF-I or serum-induced IGF-IR signaling in MM cells in vitro. The A12 as a single agent was demonstrated to exert modest to significant inhibition of tumor growth in vivo in various subcutaneous xenograft MM models. The A12 was also evaluated in a disseminated xenograft MM.1S NOD/SCID model as monotherapy or in combination with other drugs (bortezomib, melphalan) currently in clinical use. The tumor burden, as determined by luciferase bioimaging, was sharply decreased, and overall survival significantly prolonged when the therapies were combined. Immunohistochemical analysis demonstrated that the A12 treated tumors had significantly decreased vascularization compared to control tumors. Furthermore, most MM lines constitutively secreted significant quantities of VEGF, and this was enhanced following IGF-I treatment. Inhibition of IGF-IR by the A12 in vitro suppressed both constitutive and IGF-I-induced secretion of VEGF, indicating that a putative anti-angiogenic mechanism associated with the A12 treatment may contribute to its anti-tumor effect.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/pharmacology
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/immunology
- Antineoplastic Agents/pharmacology
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Boronic Acids/administration & dosage
- Bortezomib
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Cell Survival/drug effects
- Disease Models, Animal
- Female
- Humans
- Injections, Intravenous
- Injections, Subcutaneous
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Multiple Myeloma/drug therapy
- Multiple Myeloma/immunology
- Multiple Myeloma/pathology
- Neovascularization, Pathologic/drug therapy
- Pyrazines/administration & dosage
- Receptor, IGF Type 1/antagonists & inhibitors
- Receptor, IGF Type 1/biosynthesis
- Receptor, IGF Type 1/immunology
- Structure-Activity Relationship
- Survival Rate
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Kai-Da Wu
- James Ewing Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 USA
| | - Li Zhou
- James Ewing Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 USA
| | | | | | - Malcolm A. S. Moore
- James Ewing Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 USA
| |
Collapse
|
13
|
Ludwig DL, Witte L, Hicklin DJ, Prewett M, Bassi R, Burtrum D, Pereira DS, Jimenez X, Fox F, Saxena B, Zhou Q, Ma Y, Kang X, Patel D, Barry M, Kussie P, Zhu Z, Russell DA, Petersen WL, Jury TP, Gaitan-Gaitan F, Moran DL, Delannay X, Storrs BS, Tou J, Zupec ME, Gustafson KS, McIntyre J, Tarnowski SJ, Bohlen P. Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed. Hum Antibodies 2004; 13:81-90. [PMID: 15598988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
Recombinant protein production in plants such as corn is a promising means to generate high product yields at low comparable production cost. The anti-EGFR monoclonal antibody C225, cetuximab, is a well-characterized receptor antagonist antibody recently approved for the treatment of refractory colorectal cancer. We initiated a study to test and compare the functional activity of glycosylated and aglycosylated C225 produced in stable transgenic corn seed. Both corn antibodies were shown to be functionally indistinguishable from mammalian-derived C225 in demonstrating high-affinity binding to the EGF receptor, blocking of ligand-dependent signaling, and inhibiting cell proliferation. In addition, consistent with cetuximab, both corn antibodies possessed strong anti-tumor activity in vivo. Acute dose primate pharmacokinetic studies, however, revealed a marked increase in clearance for the glycosylated corn antibody, while the aglycosylated antibody possessed in vivo kinetics similar to cetuximab. This experimentation established that corn-derived receptor blocking monoclonal antibodies possess comparable efficacy to mammalian cell culture-derived antibody, and offer a cost effective alternative to large-scale mammalian cell culture production.
Collapse
Affiliation(s)
- Dale L Ludwig
- ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63:8912-21. [PMID: 14695208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
The insulin-like growth factor I receptor (IGF-IR) is overexpressed in many diverse tumor types and is a critical signaling molecule for tumor cell proliferation and survival. Therapeutic strategies targeting the IGF-IR may therefore be effective broad-spectrum anticancer agents. Through screening of a Fab phage display library, we have generated a fully human antibody (A12) that binds to the IGF-IR with high affinity (4.11 x 10(-11) M) and inhibits ligand binding with an IC(50) of 0.6-1 nM. Antibody-mediated blockade of ligand binding to the IGF-IR inhibited downstream signaling of the two major insulin-like growth factor (IGF) pathways, mitogen-activated protein kinase and phosphatidylinositol 3'-kinase/Akt, in MCF7 human breast cancer cells. As a result, the mitogenic and proliferative potential of IGF-I and IGF-II were significantly reduced. A12 did not block insulin binding to the insulin receptor but could block binding to atypical IGF-IR in MCF7 cells. In addition, A12 was shown to induce IGF-IR internalization and degradation on specific binding to tumor cells, resulting in a significant reduction in cell surface receptor density. In xenograft tumor models in vivo, IGF-IR blockade by A12 was shown to occur rapidly, resulting in significant growth inhibition of breast, renal, and pancreatic tumors. Histological analysis of tumor sections demonstrated a marked increase in apoptotic tumor cells in antibody-treated animals. These results demonstrate that A12 possesses strong antitumor activity in vitro and in vivo and may therefore be an effective therapeutic candidate for the treatment of cancers that are dependent on IGF-IR signaling for growth and survival.
Collapse
|
15
|
Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, Zhu Z. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2003; 279:2856-65. [PMID: 14576153 DOI: 10.1074/jbc.m310132200] [Citation(s) in RCA: 106] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Both the epidermal growth factor receptor (EGFR) and the insulin-like growth factor receptor (IGFR) have been implicated in the tumorigenesis of a variety of human cancers. Effective tumor inhibition has been achieved both experimentally and clinically with a number of strategies that antagonize either receptor activity. Here we constructed and produced two fully human recombinant bispecific antibodies (BsAb) that target both EGFR and IGFR, using two neutralizing human antibodies originally isolated from a phage display library. The BsAb not only retained the antigen binding capacity of each of the parent antibodies, but also were capable of binding to both targets simultaneously as demonstrated by a cross-linking enzyme-linked immunosorbent assay. Furthermore, the BsAb effectively blocked both ligands, EGF and IGF, from binding to their respective receptors, and inhibited tumor cell proliferation as potently as a combination of both the parent antibodies. More importantly, the BsAb were able to completely block activation of several major signal transduction molecules, including Akt and p44/p42 MAP kinases, by both EGF and IGF, whereas each individual parent antibody was only effective in inhibiting those signal molecules activated by the relevant single growth factor. The BsAb molecules retained good antigen binding activity after incubation with mouse serum at 37 degrees C for up to 6 days. Taken together, our results underscore the benefits of simultaneous targeting multiple growth factor receptor pathways for more efficacious cancer treatment. This report describes the first time use of a recombinant BsAb for targeting two tumor-associated molecules on either a single or adjacent tumor cells for enhanced antitumor activity.
Collapse
Affiliation(s)
- Dan Lu
- Department of Antibody Technology, ImClone Systems Incorporated, New York, New York 10014, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med 1996; 183:2219-26. [PMID: 8642331 PMCID: PMC2192544 DOI: 10.1084/jem.183.5.2219] [Citation(s) in RCA: 223] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Expression of the bcl-2 gene has been shown to effectively confer resistance to programmed cell death under a variety of circumstances. However, despite a wealth of literature describing this phenomenon, very little is known about the mechanism of resistance. In the experiments described here, we show that bcl-2 gene expression can result in an inhibition of cell division cycle progression. These findings are based upon the analysis of cell cycle distribution, cell cycle kinetics, and relative phosphorylation of the retinoblastoma tumor suppressor protein, using primary tissues in vivo, ex vivo, and in vitro, as well as continuous cell lines. The effects of bcl-2 expression on cell cycle progression appear to be focused at the G1 to S phase transition, which is a critical control point in the decision between continued cell cycle progression or the induction programmed cell death. In all systems tested, bcl-2 expression resulted in a substantial 30-60% increase in the length of G1 phase; such an increase is very substantial in the context of other regulators of cell cycle progression. Based upon our findings, and the related findings of others, we propose a mechanism by which bcl-2 expression might exert its well known inhibition of programmed cell death by regulating the kinetics of cell cycle progression at a critical control point.
Collapse
Affiliation(s)
- S Mazel
- Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | | |
Collapse
|
17
|
Abstract
The antigen-specific receptors of T and B lymphocytes are generated by somatic recombination between noncontiguous gene segments encoding the variable portions of these molecules. The semirandom nature of this process, while desirable for the generation of diversity, has been thought to exact a high price in terms of sterile (out-of-frame) products. Historically, the majority of T lymphocytes generated in mammals were thought to be useless, either because they generated such sterile rearrangements or because the receptors generated did not appropriately recognize self-molecules (i.e., positive and negative selection). In the studies described here, we characterize the onset of T cell receptor (TCR) alpha and beta chain gene rearrangements and quantitate their progression throughout T cell development. The results show that T cell production efficiency is enhanced through (a) rearrangement of TCR-beta chain genes early during T cell development, with selective expansion of those cells possessing in-frame rearrangements; (b) deletion of sterile rearrangements at the TCR-alpha chain locus through ordered (proximal to distal) sequential recombination; and (c) modification of nonselectable alpha/beta heterodimer specificities through generation and expression of new TCR-alpha chains. In addition, we demonstrate strict correlations between successful TCR-beta gene rearrangement, the onset of TCR-alpha gene rearrangement, rapid cell division, and programmed cell death, which together serve to maintain cell turnover and homeostasis during T cell development.
Collapse
MESH Headings
- Animals
- Apoptosis
- Cell Differentiation
- Gene Rearrangement, T-Lymphocyte
- Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor
- Gene Rearrangement, beta-Chain T-Cell Antigen Receptor
- Homeostasis
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Proto-Oncogene Proteins/biosynthesis
- Proto-Oncogene Proteins/genetics
- Proto-Oncogene Proteins/physiology
- Proto-Oncogene Proteins c-bcl-2
- Receptors, Antigen, T-Cell, alpha-beta/genetics
- Receptors, Interleukin-2/biosynthesis
- Recombination, Genetic
- T-Lymphocyte Subsets
Collapse
Affiliation(s)
- H T Petrie
- Immunology Program, Memorial Sloan-Kettering Cancer Center, New York 10021, USA
| | | | | | | |
Collapse
|
18
|
Abstract
BACKGROUND AND PURPOSE We tested the hypothesis that cerebral hypoxia-ischemia selectively stimulates interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) gene expression in brain regions susceptible to irreversible injury in perinatal rats. METHODS To elicit focal hypoxic-ischemic brain injury, 7-day-old perinatal (P7) rats were subjected to right carotid artery ligation followed by 3 hours of 8% O2 exposure and were killed 0 to 48 hours after hypoxia. Regional tissue IL-1 beta and TNF-alpha mRNA content were measured by reverse transcription followed by polymerase chain reaction amplification (RT-PCR) in samples prepared from cortex and hippocampus of the lesioned and contralateral hemispheres. cDNAs were amplified with primers specific for IL-1 beta, TNF-alpha, and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which served as an internal control. The RT-PCR products were subjected to Southern blot analysis and hybridized with 32P-labeled gene-specific probes. Radioactivity was measured in excised bands, and results were normalized on the basis of levels of GAPDH expression. RESULTS In unlesioned P7 brain, IL-1 beta mRNA was barely detectable. In lesioned forebrain, there was a marked, transient stimulation of IL-1 beta mRNA expression, peaking at 4 hours after hypoxia. Hybridization signal was increased 16- to 30-fold over values from contralateral hemisphere samples in three independent assays (P < .05 comparing values in left and right cortex and in left and right hippocampus with the Kruskal-Wallis ranking test); by 24 hours after hypoxia, levels returned to normal. Similar transient increases in TNF-alpha mRNA expression were detected. In a closely related model of perinatal brain injury elicited by focal intracerebral N-methyl-D-aspartate injection, there was a corresponding acute stimulation of IL-1 beta and TNF-alpha mRNA expression at 4 hours after injection. CONCLUSIONS These results suggest that IL-1 beta and TNF-alpha may play important roles in the response of the developing brain to acute hypoxic-ischemic injury.
Collapse
Affiliation(s)
- J Szaflarski
- Department of Pediatrics, University of Michigan, Ann Arbor 48109-0646, USA
| | | | | |
Collapse
|
19
|
Abstract
Accumulation of glial fibrillary acidic protein xk(G-FAP) in reactive astrocytes is a characteristic neuropathologic feature of ischemic brain injury. We examined injury-induced changes in GFAP mRNA and protein in a well-characterized model of focal hypoxic-ischemic injury in perinatal rodent brain. Postnatal Day (PND) 7 rats underwent right carotid artery ligation followed by 2.5 h exposure to 8% oxygen, which results in injury to ipsilateral cortex, hippocampus, and striatum in the majority of animals. Using Northern analysis, we assayed GFAP mRNA in samples from the lesioned and contralateral hemispheres of animals killed 1 h to 14 days later, and from animals treated with the neuroprotective glutamate antagonist MK-801. GFAP immunoreactivity in tissue homogenates from the lesioned and contralateral hemispheres was also compared with an immunoblot assay. One and 4 h posthypoxia GFAP mRNA expression was barely detectable. In the lesioned cortex, increased GFAP mRNA was detected at 24 h postinjury; over the next 2 weeks GFAP mRNA was consistently higher (at least 2-fold) in lesioned than in contralateral cortex. In contrast, in lesioned hippocampus and striatum, consistent increases in GFAP mRNA were first detected on PND 12. Immunoassays of GFAP demonstrated early (PND 8) and sustained (to PND 21) up to 10-fold increases in lesioned cortex, hippocampus, and striatum. In this perinatal stroke model regionally specific increases in GFAP mRNA expression and GFAP immunoreactivity are detected in the first 2 weeks after hypoxic-ischemic injury; intrinsic properties of glia and/or neurons in different brain regions may influence the timing and magnitude of stimulation of this response.
Collapse
Affiliation(s)
- D Burtrum
- Department of Pediatrics, University of Michigan, Ann Arbor 48109-0570
| | | |
Collapse
|
20
|
Abstract
To study the molecular mechanisms contributing to glial fibrillary acidic protein (GFAP) accumulation after neuronal injury in the developing brain, we used a reproducible and pharmacologically modifiable model of excitotoxic injury, intracerebral injection of N-methyl-D-aspartate (NMDA) in Postnatal Day 7 rats. Injection of NMDA into the posterior striatum elicits dose-dependent ipsilateral injury to striatum, hippocampus, and overlying cortex; treatment with the non-competitive NMDA antagonist MK-801 is neuroprotective. To examine regionally specific changes in GFAP mRNA expression after lesioning, GFAP mRNA content was assayed, by Northern analysis, in pooled tissue samples of striatum, hippocampus, and cortex, derived from the injected and contralateral hemispheres of animals killed 1-16 days after lesioning with NMDA (12.5 nmol), and in samples derived from lesioned animals and littermates treated with MK-801. In addition, in situ hybridization assays were done to visualize the anatomic distribution of GFAP mRNA expression in NMDA-lesioned (n = 5) and lesioned/MK-801-treated animals (n = 3) 5 days postinjection. There was a marked rise in GFAP mRNA in lesioned cortex within 24 h, and increases were sustained over the next 2 weeks. In contrast, in striatum and hippocampus, in which severe histologic damage evolves, at 24 h postlesioning there was little stimulation of GFAP mRNA expression. Subsequently, 5-16 days postinjury increases in GFAP mRNA were detected in both brain regions. In animals examined 5 days postlesioning, MK-801 treatment markedly attenuated stimulation of GFAP mRNA expression.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- D Burtrum
- Department of Pediatrics, University of Michigan, Ann Arbor 48109-0570
| | | |
Collapse
|